Cargando…
Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645553/ http://dx.doi.org/10.1186/2051-1426-3-S2-P129 |
_version_ | 1782400838653706240 |
---|---|
author | Chandar, Ashwin Silk, Ann W Clark, Joseph I Daniels, Gregory A McDermott, David F Morse, Michael Wong, Michael KK Stein, Mark Mehnert, Janice Danish, Shabbar Aung, Sandra Kaufman, Howard L |
author_facet | Chandar, Ashwin Silk, Ann W Clark, Joseph I Daniels, Gregory A McDermott, David F Morse, Michael Wong, Michael KK Stein, Mark Mehnert, Janice Danish, Shabbar Aung, Sandra Kaufman, Howard L |
author_sort | Chandar, Ashwin |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-4645553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46455532015-11-20 Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma Chandar, Ashwin Silk, Ann W Clark, Joseph I Daniels, Gregory A McDermott, David F Morse, Michael Wong, Michael KK Stein, Mark Mehnert, Janice Danish, Shabbar Aung, Sandra Kaufman, Howard L J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645553/ http://dx.doi.org/10.1186/2051-1426-3-S2-P129 Text en Copyright © 2015 Chandar et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Poster Presentation Chandar, Ashwin Silk, Ann W Clark, Joseph I Daniels, Gregory A McDermott, David F Morse, Michael Wong, Michael KK Stein, Mark Mehnert, Janice Danish, Shabbar Aung, Sandra Kaufman, Howard L Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma |
title | Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma |
title_full | Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma |
title_fullStr | Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma |
title_full_unstemmed | Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma |
title_short | Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma |
title_sort | efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma |
topic | Poster Presentation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645553/ http://dx.doi.org/10.1186/2051-1426-3-S2-P129 |
work_keys_str_mv | AT chandarashwin efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma AT silkannw efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma AT clarkjosephi efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma AT danielsgregorya efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma AT mcdermottdavidf efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma AT morsemichael efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma AT wongmichaelkk efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma AT steinmark efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma AT mehnertjanice efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma AT danishshabbar efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma AT aungsandra efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma AT kaufmanhowardl efficacyandsafetyofhighdoseinterleukin2treatmentinpatientswithahistoryofbrainmetastasesfromrenalcellcarcinoma |